Editorial Material
Gastroenterology & Hepatology
Satya Priya Sharma, Ki Tae Suk, Dong Joon Kim
Summary: The review highlights the crucial role of gut microbes in maintaining liver homeostasis and the impact of dysbiosis on the development of fatty liver disease. The changes in gut microbial composition in alcoholic and nonalcoholic fatty liver diseases and how they contribute to the pathophysiology of the disease are discussed. New approaches related to gut microbes for the diagnosis and treatment of fatty liver disease are also summarized.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Review
Physiology
Dongqing Wu, Huaqing Zhu, Hua Wang
Summary: The liver, as the largest vital solid organ in the body, consists of multiple types of cells that communicate critically to maintain liver function homeostasis. Extracellular vesicles (EVs) play a significant role in cell-to-cell communication and are involved in the development of liver diseases.
FRONTIERS IN PHYSIOLOGY
(2021)
Review
Health Care Sciences & Services
Laura Valenzuela-Vallejo, Despina Sanoudou, Christos S. Mantzoros
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease with various complications. The lack of non-invasive diagnosis and effective treatment calls for a more specific subcategorization of fatty liver disease (FLD). A precision medicine approach based on subcategorization is expected to improve patient care and reduce healthcare costs associated with FLD.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Review
Gastroenterology & Hepatology
Sakura Yamamura, Dan Nakano, Ryuki Hashida, Tsubasa Tsutsumi, Takumi Kawaguchi, Michiaki Okada, Hiroshi Isoda, Hirokazu Takahashi, Hiroo Matsuse, Yuichiro Eguchi, Yoshio Sumida, Atsushi Nakajima, Lynn Gerber, Zobair M. Younossi, Takuji Torimura
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide and it is important to assess all associated outcomes including patient-reported outcomes (PROs). The Chronic Liver Disease Questionnaire (CLDQ)-NAFLD/NASH is a specific instrument developed for this purpose and has shown excellent reliability and validity in international clinical trials.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Lui Ng, Ryan Wai-Yan Sin, David Him Cheung, Wai-Keung Leung, Abraham Tak-Ka Man, Oswens Siu-Hung Lo, Wai-Lun Law, Dominic Chi-Chung Foo
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease that is increasing worldwide, and it is associated with colorectal polyps. This study aimed to investigate the potential of serum microRNAs (miRNAs) in identifying NAFLD in colorectal polyp patients. The results showed that a serum miRNA panel composed of four miRNA pairs significantly identified NAFLD in colorectal polyp patients, and its performance improved when patients with other concurrent metabolic disorders were removed from the analysis. The serum miRNA panel could be a potential diagnostic biomarker for screening NAFLD in colorectal polyp patients for early diagnosis and prevention of disease progression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Cell Biology
Daryl Ramai, Antonio Facciorusso, Erika Vigandt, Bryan Schaf, Waleed Saadedeen, Aditya Chauhan, Sara di Nunzio, Aashni Shah, Luca Giacomelli, Rodolfo Sacco
Summary: NASH is a chronic and progressive form of non-alcoholic fatty liver disease with increasing global incidence, posing an epidemic and public health threat. The disease is associated with major morbidity and mortality, with patients at risk of developing hepatocellular carcinoma. Current evidence suggests a multi-hit model involving various pathways leading to progressive fibrosis and oncogenesis, highlighting the complexity of the disease.
Article
Biochemistry & Molecular Biology
Marcin Kosmalski, Jozef Drzewoski, Izabela Szymczak-Pajor, Andrzej Zieleniak, Melania Mikolajczyk-Solinska, Jacek Kasznicki, Agnieszka Sliwinska
Summary: The study aimed to evaluate the association between Irisin and non-alcoholic fatty liver disease (NAFLD). The results showed that Irisin concentration was correlated with anthropometric and biochemical parameters, suggesting its potential as a diagnostic biomarker for NAFLD.
Letter
Gastroenterology & Hepatology
Hui-Chin Chang, Shuo-Yan Gau
Summary: This article is associated with Park et al papers. To access and view these articles, please visit.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Medicine, General & Internal
Guanlin Li, Xinrong Zhang, Huapeng Lin, Lilian Yan Liang, Grace Lai-Hung Wong, Vincent Wai-Sun Wong
Summary: New developments in non-invasive assessment methods show potential in diagnosing and monitoring NAFLD. Magnetic resonance imaging and blood biomarkers can be used to detect hepatic steatosis and fibrosis, but further research is needed to confirm their role in treatment monitoring.
CHINESE MEDICAL JOURNAL
(2022)
Review
Biochemistry & Molecular Biology
Ji-Won Park, Sung-Eun Kim, Na Young Lee, Jung-Hee Kim, Jang-Han Jung, Myoung-Kuk Jang, Sang-Hoon Park, Myung-Seok Lee, Dong-Joon Kim, Hyoung-Su Kim, Ki Tae Suk
Summary: Chronic liver disease, including alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD), is influenced by gut microbiota dysregulation through the gut-liver axis. The gut microbiota releases various metabolites that affect host immunity and metabolism, while the integrity of the intestinal barriers is crucial in protecting the liver from harmful substances. This review discusses the pathologic effects of gut microbiota-derived metabolites in the liver and presents recent advancements in molecular-based therapies and mechanistic findings related to the gut-liver axis in ALD and NAFLD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Medicine, General & Internal
Rafael Paternostro, Michael Trauner
Summary: Non-alcoholic fatty liver disease (NAFLD) is a liver disease with various pathologies. In addition to lifestyle changes and a few specific medications, there are new treatment options being studied. Treating complications of end-stage liver disease caused by non-alcoholic steatohepatitis (NASH) is important for the treatment of the complete clinical spectrum of NAFLD.
JOURNAL OF INTERNAL MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Aleksandra Hliwa, Bruno Ramos-Molina, Dariusz Laski, Adriana Mika, Tomasz Sledzinski
Summary: Non-alcoholic fatty liver disease (NAFLD) is a major global public health problem characterized by alterations in hepatic lipid metabolism that can lead to serious liver complications. Mass spectrometry-based lipidomics platforms allow for in-depth analysis of lipid changes in NAFLD patients, focusing on alterations in long-chain and short-chain fatty acids levels as well as the expression of genes encoding lipid interconversion enzymes in the liver.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Gastroenterology & Hepatology
Seul Ki Han, Soon Koo Baik, Moon Young Kim
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide, with a prevalence of approximately 30%. Its prevalence varies depending on comorbidities and is expected to increase due to the rising obesity rates. NAFLD is a major cause of chronic liver diseases, including cirrhosis and hepatocellular carcinoma (HCC). This article provides a brief overview of NAFLD's definition and classification based on current knowledge.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Review
Pharmacology & Pharmacy
Andrea Dalbeni, Marco Castelli, Mirko Zoncape, Pietro Minuz, David Sacerdoti
Summary: Non alcoholic steatohepatitis (NASH) is an inflammatory reaction of the liver caused by excessive accumulation of lipids in hepatocytes. It can lead to cirrhosis and hepatocellular carcinoma (HCC). Fatty liver is a manifestation of metabolic syndrome, which is associated with subclinical inflammation. Platelets are involved in immune response and activation of stellate cells, and may play a key role in the development of NASH. Antiplatelet drugs have been shown to interrupt this process and improve NASH and metabolic alterations.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Gastroenterology & Hepatology
Kai Zhu, Rohan Kakkar, Daljeet Chahal, Eric M. Yoshida, Trana Hussaini
Summary: Semaglutide is effective in the treatment of NAFLD, leading to improved liver histology, reduced liver stiffness, and improved cardiometabolic outcomes. It also has a well-tolerated safety profile, although it may increase the occurrence of gastrointestinal side effects.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Yoon Suk Jung, Nam Hee Kim, Hyo-Joon Yang, Soo-Kyung Park, Jung Ho Park, Dong Il Park, Chong Il Sohn
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2020)
Article
Gastroenterology & Hepatology
Hyo-Joon Yang, Dong Il Park, Soo-Kyung Park, Chang Kyun Lee, Hyo Jong Kim, Shin Ju Oh, Jung Rock Moon, Beom Jae Lee, Jin Sung Koh, Hyun Soo Kim, Seon-Young Park, Dong Hyun Kim, Jaeyoung Chun, Eun Ae Kang, Jung Kim, Hosim Soh, Chang Soo Eun, You Sun Kim, Yoon Tae Jeen
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2020)
Article
Gastroenterology & Hepatology
Soo-Kyung Park, Sang Hyun Park, Hyo-Joon Yang, Yoon Suk Jung, Jung Ho Park, Chong Il Sohn, Dong Il Park
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2020)
Article
Gastroenterology & Hepatology
Kyung Mo Yoo, Hyo-Joon Yang, Soo-Kyung Park, Yoon Suk Jung, Jung Ho Park, Dong Il Park, Chong Il Sohn
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2020)
Article
Gastroenterology & Hepatology
Hyunbeom Chae, Hyo-Joon Yang, Soo-Kyung Park, Yoon Suk Jung, Jung Ho Park, Dong Il Park, Chong Il Sohn
Summary: The study found that metabolically healthy obese individuals and metabolically abnormal obese individuals have an increased risk of colorectal adenoma occurrence, while there was no increased risk in metabolically abnormal nonobese individuals.
Article
Gastroenterology & Hepatology
Chan Hyuk Park, Yoon Suk Jung, Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn
Summary: The study aimed to develop a risk scoring model for predicting advanced colorectal neoplasia (ACRN) during surveillance, incorporating clinical factors and index colonoscopy findings. Age, abdominal obesity, advanced adenoma, and the number of adenomas at index colonoscopy were identified as risk factors for metachronous ACRN, with different risk categories based on assigned point scores showing varying ACRN risks and recommended surveillance intervals.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Jun Ki Min, Hyo-Joon Yang, Min Seob Kwak, Chang Woo Cho, Sangsoo Kim, Kwang-Sung Ahn, Soo-Kyung Park, Jae Myung Cha, Dong Il Park
Summary: This study compared DNN models with simple clinical score models in predicting the risk of advanced colorectal neoplasia, finding that simple score models are as effective as DNN models when input variables are limited. Further studies are needed to improve DNN-based models for predicting the risk of ACRN in colorectal cancer screening.
Article
Gastroenterology & Hepatology
Shin Ju Oh, Ga Young Shin, Hosim Soh, Jae Gon Lee, Jong Pil Im, Chang Soo Eun, Kang-Moon Lee, Dong Il Park, Dong Soo Han, Hyo Jong Kim, Chang Kyun Lee
Summary: This study demonstrated that infliximab (IFX) is an effective therapeutic option for Korean patients with acute severe ulcerative colitis (ASUC), regardless of IFX indication. Aggressive vigilance for cytomegalovirus colitis and Clostridioides difficile infection is essential for hospitalized ASUC patients to prevent colectomy.
INTESTINAL RESEARCH
(2021)
Article
Gastroenterology & Hepatology
Yehyun Park, Chang Hwan Choi, Hyun Soo Kim, Hee Seok Moon, Do Hyun Kim, Jin Ju Kim, Dennis Teng, Dong Il Park
Summary: This study investigated the use of steroids in South Korean patients with inflammatory bowel disease (IBD) and found that approximately one-third of patients used steroids excessively, with one-third of these individuals using excessive steroids inappropriately. Severe disease activity was associated with excessive steroid use in cases with ulcerative colitis.
INTESTINAL RESEARCH
(2022)
Article
Gastroenterology & Hepatology
Eun Soo Kim, Chung Hyun Tae, Sung-Ae Jung, Dong Il Park, Jong Pil Im, Chang Soo Eun, Hyuk Yoon, Byung Ik Jang, Haruhiko Ogata, Kayoko Fukuhara, Fumihito Hirai, Kazuo Ohtsuka, Jing Liu, Qian Cao
Summary: This study investigated the prevalence and pattern of CAM use among East Asian IBD patients and identified factors associated with CAM use. The results showed that 8.6% of patients used CAM services for their disease, while 29.7% of patients sought at least one kind of CAM product. Current active disease and Chinese or South Korean nationality were independent predictors of CAM use.
INTESTINAL RESEARCH
(2022)
Article
Medicine, Research & Experimental
Dong W. Kim, Yousun Lee, Geuntae Kim, Sang H. Kim, Dae H. Cho, Jeongmin Choi, Yong H. Kwon, Younjin Park, Wooree Choi, Dong I. Park
Summary: This study confirmed the safety and effectiveness of SB2 in major indications.
ADVANCES IN THERAPY
(2023)
Article
Medicine, General & Internal
Yoon Suk Jung, Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn
YONSEI MEDICAL JOURNAL
(2020)
Article
Oncology
Yoon Suk Jung, Jung Ho Park, Dong Il Park, Chong Il Sohn, Jae Myun Lee, Tae Il Kim
JOURNAL OF CANCER PREVENTION
(2020)
Review
Gastroenterology & Hepatology
Soo-Kyung Park, Chang Hwan Choi, Jaeyoung Chun, Heeyoung Lee, Eun Sun Kim, Jae Jun Park, Chan Hyuk Park, Bo-In Lee, Yunho Jung, Dong-Il Park, Do Young Kim, Hana Park, Yoon Tae Jeen
INTESTINAL RESEARCH
(2020)
Article
Gastroenterology & Hepatology
Masayuki Saruta, Dong Il Park, Young-Ho Kim, Suk-Kyun Yang, Byung-Ik Jang, Jae Hee Cheon, Jong Pil Im, Takanori Kanai, Tatsuro Katsuno, Yoh Ishiguro, Makoto Nagaoka, Naoki Isogawa, Yinhua Li, Anindita Banerjee, Alaa Ahmad, Mina Hassan-Zahraee, Robert Clare, Kenneth J. Gorelick, Fabio Cataldi, Mamoru Watanabe, Toshifumi Hibi
INTESTINAL RESEARCH
(2020)